AI transparency: articles and reports are produced with the help of artificial intelligence and checked through a process that does not constitute specialist validation. They may contain errors: verify relevant information with independent sources. Read the full disclaimer.

Biotech Catalysts December 2026: PDUFA Dates, Clinical Data and Medical Congresses

209 biotech and healthcare catalysts across 141 companies are scheduled for December 2026, including 8 FDA decision dates (PDUFA), 29 clinical data readouts that companies expect during the month, 78 presentations at medical and scientific congresses and 94 investor conferences and corporate events. Every entry links to its primary source: company press releases, SEC filings, FDA documents or trial registries.

Dates can change. A PDUFA date is a review goal, not a promise of approval, and company timing guidance for data readouts can slip. The list is updated every day: events that move out of the month are removed, and events that have taken place move to the past-events section at the bottom of the page.

Data as of November 18, 2026, 19:17 Europe/Rome — 209 upcoming events. Daily calendar: Biotech Catalyst Calendar · Full list: Catalyst Total Tracker

FDA decisions · Clinical data · Medical congresses · Investor and corporate events

FDA decision dates (PDUFA) in December 2026

FDA decisions: 8 events

Date / windowTickerCompanyEventStatusSources
2026-12-12$ANABANAPTYSBIO, INCQuimilza (imsidolimab) for generalized pustular psoriasis, with Vanda as AnaptysBio's partner: the FDA target action date is December 12, 2026.Confirmed dateSEC filing
2026-12-12$VNDAVanda Pharmaceuticals Inc.Imsidolimab, IL-36R antagonist — generalized pustular psoriasis molecule originated by AnaptysBio, BLA held by Vanda.Confirmed datePrimary source
2026-12-17$CORTCorcept Therapeutics IncorporatedRelacorilant, selective glucocorticoid receptor antagonist — Cushing's syndrome NDA resubmitted on 17 June 2026 after a CRL on this indication.Confirmed dateSEC filing
2026-12-22$MLYSMineralys Therapeutics, Inc.Lorundrostat NDA for the treatment of hypertension in adults, in combination with other antihypertensive drugs: the FDA target action date (PDUFA) is December 22, 2026.Confirmed datePrimary source
2026-12-23$GILDGILEAD SCIENCES, INC.Anito-cel (anitocabtagene autoleucel), anti-BCMA CAR-T — relapsed or refractory multiple myeloma, fourth line BLA filed by Arcellx, acquired by Gilead on 28 April 2026.Confirmed dateSEC filing
2026-12-27$PRAXPraxis Precision Medicines, Inc.Relutrigine NDA for SCN2A and SCN8A developmental and epileptic encephalopathies: the FDA target action date was extended from September 27, 2026 to December 27, 2026 following a major amendment to the application.Confirmed datePrimary source
2026-12-27$VTRSViatris Inc.PDUFA goal date for Viatris' New Drug Application (505(b)(2) pathway) for MR-107A-02, an investigational fast-acting oral formulation of meloxicam (NSAID) for the treatment of moderate-to-severe acute pain, positioned as a non-opioid option; the FDA accepted the NDA for review, as announced on May 18, 2026. The product has not been approved by any regulatory authority.Confirmed datePrimary source
Supporting source
2026-12-30$COGTCogent Biosciences, Inc.Bezuclastinib monotherapy — non-advanced systemic mastocytosis.Confirmed datePrimary source

Clinical data readouts expected in December 2026

Companies have guided to these readouts during December without naming a day. Timing comes from company statements and can move into the following month.

Expected clinical data: 29 events

Date / windowTickerCompanyEventStatusSources
2026-12-18$ANIPANI PHARMACEUTICALS INCThe acceptance period for ANI Pharmaceuticals' offer to acquire Egetis Therapeutics is expected to expire on or around 2026-12-18, according to the November 16, 2026 investor presentation. The expected dates are subject to change and the acquisition remains subject to closing conditions.Estimated windowSEC filing
Mid-December 2026$FBLGFibroBiologics, Inc.FibroBiologics expects to report initial safety data from the sentinel cohort of its Phase 1/2 trial of CYWC628 in diabetic foot ulcers in mid-December 2026. No exact date announced.Estimated windowPrimary source
December 2026$ABSIABSCI CORPAbsci anticipates reporting 13-week interim proof-of-concept data for ABS-201 in androgenetic alopecia (pattern hair loss) in December 2026, with full 26-week proof-of-concept data in early 2027. Exact day not announced.Estimated windowPrimary source
December 2026$ALLOAllogene Therapeutics, Inc.Allogene Therapeutics plans to host an in-person investor event at the ASH Annual Meeting (December 2026) on how cema-cel could help overcome longstanding barriers to CAR T adoption (update of November 5, 2026).Estimated windowSEC filing
December 2026$ALTAltimmune, Inc.Altimmune is scheduled to meet with the FDA in December 2026 for an End-of-Phase 2 meeting to discuss the Phase 3 registrational program for pemvidutide in alcohol use disorder (AUD), according to its release of November 5, 2026. Exact day not announced.Estimated windowPrimary source
December 2026$ALXOALX Oncology Holdings Inc.ALX Oncology expects to report dose-escalation safety and early efficacy data from the ongoing Phase 1 trial (NCT07085091) of ALX2004, an EGFR-targeted antibody-drug conjugate, in patients with advanced or metastatic select EGFR-expressing solid tumors in December 2026, and plans to host a KOL webinar to review the safety and efficacy results from the 35-40 patients enrolled to date. No specific day has been announced.Estimated windowPrimary source
2026-12-31$ANVSAnnovis Bio, Inc.Last patient, last visit of the 6-month treatment period in the Phase 3 DUET-AD study of buntanetap in early Alzheimer's disease is scheduled for December 31, 2026, with database lock on February 8, 2027 and topline results in March 2027.Estimated windowSEC filing
December 2026$ARGXARGENX SEargenx said in its Q3 2026 results release (October 22, 2026) that topline results from the Phase 3 EMPASSION study of empasiprubart (ARGX-117, anti-C2) in multifocal motor neuropathy (MMN) are expected in December 2026. Exact event day not announced.Estimated windowSEC filing
December 2026$ATOSAtossa Therapeutics, Inc.Atossa will present Karisma follow-up results and selected data from the I-SPY2 study of (Z)-endoxifen in combination with elagolix and with abemaciclib at the San Antonio Breast Cancer Symposium (SABCS) in December 2026; presentation day not specified.Estimated windowSEC filing
As early as year-end 2026$BEAMBeam Therapeutics Inc.Beam Therapeutics anticipates submitting a Biologics License Application (BLA) for ristoglogene autogetemcel (risto-cel) in sickle cell disease as early as year-end 2026. Year-end 2026 is the earliest timing indicated by the company; no exact date is announced.Estimated windowPrimary source
December 2026$BFRIBiofrontera Inc.Biofrontera expects in December 2026 an additional $1.0 million in milestone payments from the sale of the Xepi intangible asset, contingent on the purchaser achieving specified production and commercialization milestones; the company states that receipt of the payment is not within its control (Form 10-Q for the quarter ended September 30, 2026, filed November 13, 2026). Exact day not announced.Estimated windowSEC filing
December 2026$CGEMCullinan Therapeutics, Inc.CLN-978: concurrent multidose and single-target-dose clinical data in systemic lupus erythematosus, rheumatoid arthritis and Sjögren's disease, expected in December 2026. One planned package across three indications. Exact event day is not announced.Estimated windowSEC filing
December 2026$CGONCG Oncology, Inc.CG Oncology anticipates 12-month data from BOND-003 Cohort P (BCG-unresponsive papillary-only non-muscle-invasive bladder cancer) of cretostimogene in December 2026, according to its November 6, 2026 third-quarter release.Estimated windowSEC filing
December 2026$CGONCG Oncology, Inc.CG Oncology anticipates 12-month data from CORE-008 Cohort CX (BCG-exposed high-risk and BCG-unresponsive non-muscle-invasive bladder cancer) of cretostimogene in December 2026, according to its November 6, 2026 third-quarter release.Estimated windowSEC filing
December 2026$CNTBConnect Biopharma Holdings LimitedConnect Biopharma plans to meet with the FDA in December 2026 to gain alignment on a potential Phase 3 registrational program for rademikibart in acute exacerbations of asthma. No exact date announced.Estimated windowSEC filing
December 2026$CRISCuris, Inc.Curis expects to announce initial data from five to ten patients in its ongoing Phase 1/2 TakeAim CLL study (emavusertib in combination with the Bruton's tyrosine kinase inhibitor zanubrutinib, in chronic lymphocytic leukemia, NCT07271667) in December 2026. The company had announced dosing of the fifth patient on July 30, 2026. This is company guidance; no specific presentation venue or exact calendar date has been announced.Estimated windowSEC filing
SEC filing
December 2026$DNTHDIANTHUS THERAPEUTICS INCTopline data: claseprubart · Multifocal motor neuropathy (Phase 2). Company timing: December 2026. Exact event day is not announced.Estimated windowSEC filing
December 2026$EPRXEupraxia Pharmaceuticals Inc.RESOLVE Phase 2b interim data for EP-104GI in eosinophilic esophagitis expected in December 2026. Company guidance; no exact day announced. Separate from open-label Phase 1b/2a data being presented in October. No exact day announced.Estimated windowPrimary source
December 2026$HRMYHarmony Biosciences Holdings, Inc.Harmony will present updated 18-month data from the open-label extension of the Phase 3 ARGUS study of EPX-100 (clemizole hydrochloride) in Dravet syndrome at the American Epilepsy Society (AES) Annual Meeting in December 2026. This is open-label extension data, distinct from the randomized topline expected in mid-2027. Presentation day not announced.Estimated windowSEC filing
December 2026$IMUXImmunic, Inc.Immunic expects top-line data from the fully enrolled Phase 3 ENSURE-1 and ENSURE-2 trials of vidofludimus calcium in relapsing multiple sclerosis in December 2026, as listed in the presentation for its November 5, 2026 Progressive MS R&D Day and reaffirmed with its third-quarter 2026 results on November 13, 2026; a potential U.S. NDA submission is targeted for mid-2027 if the results are positive. Exact day not announced.Estimated windowSEC filing
Supporting source
December 2026$KODKodiak SciencesTopline results from Pivotal Analysis 1 of the Phase 3 PEAK study of KSI-101 in macular edema secondary to inflammation, covering the first 300-patient cohort, are expected in December 2026 (guidance reaffirmed in the company's September 28 DAYBREAK release). No exact release day has been announced; this readout is separate from the registry primary completion and from Pivotal Analysis 2.Estimated windowPrimary source
Supporting source
December 2026$MGTXMeiraGTx Holdings plcMeiraGTx expects submission of the Marketing Authorisation Application (MAA) to the European Medicines Agency for botaretigene sparoparvovec (bota-vec) in X-linked retinitis pigmentosa in December 2026; the dossier is complete and awaiting submission. A planned submission, not an EMA decision. Exact day not announced.Estimated windowPrimary source
December 2026$MGTXMeiraGTx Holdings plcMeiraGTx expects a single ascending dose/multiple ascending dose (SAD/MAD) study of its lead riboswitch small molecule to initiate in December 2026. Exact day not announced.Estimated windowPrimary source
December 2026$NCNANuCana plcNuCana anticipates announcing in December 2026 the results of the Phase 2 NuTide:701 expansion study of NUC-7738 in combination with pembrolizumab in PD-1 inhibitor-resistant metastatic melanoma (recruitment complete), together with the latest translational data. Exact day not announced.Estimated windowSEC filing
December 2026$NKTRNektar TherapeuticsZENITH AA, the single global registrational Phase 3 study of rezpegaldesleukin in severe-to-very-severe alopecia areata (850 patients; primary endpoint SALT Score ≤20 at Week 52), is on track to begin in December 2026, earlier than the early-2027 timing previously planned, according to Nektar Therapeutics' third-quarter 2026 release of November 12, 2026. Exact day not announced.Estimated windowPrimary source
SEC filing
SEC filing
December 2026$OLMAOlema Pharmaceuticals, Inc.Olema plans to present data from the Phase 1b/2 study of OP-3136 with fulvestrant, the Phase 1b/2 study of palazestrant with everolimus and the Phase 1b study of palazestrant with atirmociclib in ER+/HER2- advanced or metastatic breast cancer at the 2026 San Antonio Breast Cancer Symposium in December; presentation day not specified.Estimated windowSEC filing
December 2026$ORKAOruka Therapeutics, Inc.ORKA-001 Week 52 data from the Phase 2a EVERLAST-A trial are expected in December 2026; no specific day has been announced.Estimated windowPrimary source
December 2026 (SABCS)$PBYIPuma Biotechnology, Inc.On November 5, 2026, Puma Biotechnology said it anticipates presenting updated data from ALISCA-Breast1, a Phase II trial of alisertib in combination with endocrine treatment in patients with chemotherapy-naive HER2-negative, hormone receptor-positive metastatic breast cancer, at the San Antonio Breast Cancer Symposium in December 2026.Estimated windowSEC filing
December 2026$XENEXenon Pharmaceuticals Inc.Topline results of the Phase 3 X-NOVA2 study of azetukalner in major depressive disorder (enrollment complete, approximately 360 patients) are now expected in December 2026 (previously Q1 2027); no specific day has been announced.Estimated windowSEC filing

Medical and scientific congresses in December 2026

Congress presentations: 78 events

Date / windowTickerCompanyEventStatusSources
2026-12-01$IBIOiBio, Inc.iBio plans a workshop at the Amylin-Based Therapeutics Summit in Boston on December 1, 2026 at 1:00 p.m. ET. Scientific workshop; preclinical platform.Confirmed dateSEC filing
2026-12-02$CGONCG Oncology, Inc.PIVOT-006 Phase 3 topline results of cretostimogene in intermediate-risk and high-grade Ta non-muscle-invasive bladder cancer (NMIBC) to be presented as a late-breaking podium presentation at the Society of Urologic Oncology (SUO) Annual Meeting on December 2, 2026.Confirmed datePrimary source
2026-12-02$IBIOiBio, Inc.iBio plans a presentation at the Amylin-Based Therapeutics Summit in Boston on December 2, 2026 at 1:30 p.m. ET. Scientific conference presentation; preclinical platform.Confirmed dateSEC filing
2026-12-02$MDWDMediWound Ltd.MediWound will host a virtual Key Opinion Leader (KOL) event on Wednesday, December 2, 2026, at 11:00 a.m. ET, on EscharEx, its investigational biologic for debridement and facilitation of wound closure: wound care experts and the management team will discuss findings from three Phase II studies (including comparative data versus SANTYL), the design, key endpoints and planned interim sample size reassessment of the pivotal Phase III VALUE study in venous leg ulcers, the assumptions behind the Alira Health-estimated $1.05 billion U.S. annual peak sales potential, and planned expansion into diabetic foot ulcers and pressure ulcers. A live Q&A will follow, and a replay will be available on the Investors section of the company's website.Confirmed datePrimary source
2026-12-03$BHVNBiohaven Ltd.Biohaven and SK Biopharmaceuticals have agreed to close the global license for opakalim on December 3, 2026, in accordance with the terms and conditions of the agreement; the terms include $350 million at closing and $50 million one year after closing, and the HSR waiting period has cleared (investor presentation dated November 16, 2026). The closing payment had not been received as of November 16, 2026.Confirmed dateSEC filing
SEC filing
2026-12-03$EYPTEyePoint, Inc.At Eyenovate at FLORetina on December 3, 2026, EyePoint is scheduled to present LUCIA pivotal Phase 3 results on the primary efficacy and safety of bioerodible EYP-1901 (vorolanib intravitreal insert) in wet AMD (Anat Loewenstein, M.D., 9:40 a.m. CET) and a presentation on IL-6 inhibition in DME with an update on the Phase 3 COMO/CAPRI trials (Ramiro Ribeiro, M.D., Ph.D., 11:15 a.m. CET).Confirmed datePrimary source
2026-12-04$ENLVEnlivex Therapeutics Ltd.Enlivex will hold an Extraordinary General Meeting of Shareholders on Friday, December 4, 2026, beginning at 10:00 a.m. Israel time, at its offices in Nes Ziona, Israel (notice and proxy statement furnished on Form 6-K on November 17, 2026). Some subsequent closings of the registered direct offering may be postponed until shareholder approval of an increase in authorized share capital.Confirmed dateSEC filing
SEC filing
Dec 4-5, 2026$EYPTEyePoint, Inc.At the FLORetina-ICOOR 2026 Congress, EyePoint presentations are scheduled on December 4, 2026 (EYP-1901 in the management of macular disease, Tarek S. Hassan, M.D., 3:45 p.m. CET; overview of the COMO and CAPRI pivotal Phase 3 trials of EYP-1901 in DME, David S. Boyer, M.D., 4:30 p.m. CET) and on December 5, 2026 (LUCIA pivotal Phase 3 efficacy and safety results of EYP-1901 in wet AMD, Charles C. Wykoff, M.D., 12:00 p.m. CET).Conference rangePrimary source
December 4-8, 2026$XENEXenon Pharmaceuticals Inc.Xenon expects multiple new azetukalner and epilepsy data presentations at the American Epilepsy Society (AES) 2026 Annual Meeting, December 4-8, 2026, in Denver. Presentation days not specified.Conference rangeSEC filing
2026-12-09$GLSIGreenwich LifeSciences, Inc.Greenwich LifeSciences will present two posters, authored by the FLAMINGO-01 Steering Committee, at the San Antonio Breast Cancer Symposium 2026 (December 8-11) on December 9, 2026, in the poster sessions for ongoing clinical trials and late-breaking abstracts; two corresponding abstracts were accepted for publication.Confirmed datePrimary source
Dec 7-9, 2026$NTLAIntellia Therapeutics, Inc.Intellia Therapeutics will participate in the 23rd Global Cardiovascular Clinical Trialists Forum in Washington, D.C., December 7-9, 2026, according to its third-quarter 2026 release; day and format not given.Conference rangeSEC filing
December 8-11, 2026$KZIAKazia Therapeutics LimitedTwo paxalisib abstracts accepted for poster presentation at the 2026 San Antonio Breast Cancer Symposium (SABCS), December 8-11, 2026, in San Antonio, Texas: preclinical research on the distinct tumor and immune reprogramming effects of paxalisib compared with other dual PI3K/mTOR inhibitors (P4-9-18), and on suppression of local and metastatic recurrence by adjuvant PI3K/mTOR inhibition following neoadjuvant chemo-immunotherapy in a preclinical model of stage III triple-negative breast cancer (P4-10-26). Presentation days are not specified.Conference rangePrimary source
SABCS, December 8-11, 2026$PRLDPrelude Therapeutics IncorporatedUpdated preclinical data for PRT13722, Prelude's KAT6A oral degrader, have been accepted for poster presentation at the 2026 San Antonio Breast Cancer Symposium (San Antonio, TX, December 8-11, 2026), together with a Trials in Progress poster on the ongoing Phase 1 study of PRT13722. The presentation day has not been specified.Conference rangePrimary source
2026-12-12$AAPGASCENTAGE PHARMA GROUP INTERNATIONALAt the 68th American Society of Hematology (ASH) Annual Meeting in New Orleans, Ascentage Pharma Group International will present two posters on Saturday, December 12, 2026, 5:30-7:30 p.m. CT: a Phase Ib study of olverembatinib (HQP1351) combined with lisaftoclax (APG-2575) in pediatric patients with relapsed/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia (publication #1547) — as of July 7, 2026, 18 patients had been treated, the overall response rate was 90.0% (9 of 10 evaluable patients, all achieving complete remission) and the MRD-negative rate was 69.2% (9 of 13) — and preclinical data on APG-5918, an EED inhibitor, showing synergistic antitumor activity with the BCL-2 inhibitor lisaftoclax in diffuse large B-cell lymphoma models (publication #1514).Confirmed dateFinviz (news)
2026-12-12$ADCTADC Therapeutics SAAt the 68th American Society of Hematology (ASH) Annual Meeting in New Orleans, an oral presentation on loncastuximab tesirine (ZYNLONTA) consolidation after short-course R-BAC induction in BTK inhibitor-exposed relapsed/refractory mantle cell lymphoma, primary endpoint analysis of the Phase II Column trial from Fondazione Italiana Linfomi (FIL), is scheduled for Saturday, December 12, 2026, 2:45-3:00 p.m. CT (3:45-4:00 p.m. ET; abstract #238). It is one of five ZYNLONTA oral presentations at the meeting announced by ADC Therapeutics.Confirmed datePrimary source
2026-12-12$AGIOAgios Pharmaceuticals, Inc.At the 68th American Society of Hematology (ASH) Annual Meeting in New Orleans, Agios presentations on Saturday, December 12, 2026 include two oral presentations: long-term ENERGIZE open-label extension data on iron overload in thalassemia, 10:00-10:15 a.m. CT (11:00-11:15 a.m. ET; #9), and long-term hemoglobin response with mitapivat in sickle cell disease from the RISE UP open-label extension (up to 115 weeks), 5:15-5:30 p.m. CT (6:15-6:30 p.m. ET; #336); plus a poster on cardiac remodeling (#1158), 5:30-7:30 p.m. CT. In the RISE UP abstract, 62.7% (74 of 118) of patients continuing on mitapivat achieved a hemoglobin improvement during the open-label extension.Confirmed datePrimary source
2026-12-12$AUTLAutolus Therapeutics plcAt the 68th American Society of Hematology (ASH) Annual Meeting in New Orleans, Autolus will give an oral presentation on Saturday, December 12, 2026 (abstract 4498, publication number 377; Elias Jabbour, MD, MD Anderson) on the first three months after obecabtagene autoleucel (obe-cel) infusion in adult relapsed/refractory B-cell acute lymphoblastic leukemia: MRD responses continued to deepen beyond month one. The same day, a poster on initial results of the academic Phase 1 UKMRA ALARIC trial of BCMA and BCMA/CD19 CAR-T (D8, AUTO8) in relapsed/refractory AL amyloidosis (publication number 2185): all of the first four patients treated with D8 alone achieved a rapid complete haematological response, at a median five-month follow-up.Confirmed datePrimary source
2026-12-12$BEAMBEAM THERAPEUTICS INCAt the 68th American Society of Hematology (ASH) Annual Meeting in New Orleans, Beam Therapeutics will present updated data from the BEACON Phase 1/2 trial of ristoglogene autogetemcel (risto-cel) in sickle cell disease, including initial patient-reported outcomes data, in an oral presentation on Saturday, December 12, 2026, 5:00-5:15 p.m. CT (6:00-6:15 p.m. ET), abstract 335 (Ashish Gupta, M.D., MPH, University of Minnesota). The presentation has been selected for ASH's official press program.Confirmed datePrimary source
2026-12-12$CGEMCullinan Therapeutics, Inc.At the 68th American Society of Hematology (ASH) Annual Meeting in New Orleans, Cullinan Therapeutics will present two posters on Saturday, December 12, 2026 (Hall F): a Trial in Progress poster on the Phase 1b study of CLN-049 with venetoclax and azacitidine in newly diagnosed acute myeloid leukemia (poster 1640) and a poster with new preclinical data on velinotamig (CLN-803), a BCMAxCD3 T cell engager, in B-lineage cells that drive autoimmune cytopenias (poster 2384).Confirmed dateSEC filing
2026-12-12$ESLAEstrella Immunopharma, Inc.ASH 2026 Abstract #2375, "Extramedullary leukemia serves as a reservoir for systemic leukemia progression and is eradicated by ARTEMIS chimeric antibody-TCR T-cell therapy", supporting the ARTEMIS platform underlying Estrella Immunopharma's EB103, to be presented as a poster at the 68th American Society of Hematology (ASH) Annual Meeting (New Orleans, December 12-15, 2026) on Saturday, December 12, 2026, 5:30-7:30 p.m. Central Time (Session 702, CAR-T Cell Therapies: Basic and Translational: Poster I; Hall F, Ernest N. Morial Convention Center).Confirmed datePrimary source
2026-12-12$GERNGeron CorporationAt the 68th American Society of Hematology (ASH) Annual Meeting in New Orleans, Geron will present three posters on Saturday, December 12, 2026: updated results from the IMproveMF trial of imetelstat plus ruxolitinib in intermediate-1/2 or high-risk myelofibrosis (#2013), a population pharmacokinetic/pharmacodynamic analysis of hematologic response dynamics supporting the approved RYTELO (imetelstat) dosing in lower-risk myelodysplastic syndromes (#2069), and a poster on telomere maintenance in chronic myelomonocytic leukemia (#2058). The posters include post-hoc analyses; no results are reported in advance.Confirmed datePrimary source
2026-12-12$GMABGenmab A/SAt the 68th American Society of Hematology (ASH) Annual Meeting in New Orleans, Genmab epcoritamab presentations on Saturday, December 12, 2026 include four oral presentations, among them first results of EPCORE CLL-1 with epcoritamab plus venetoclax in relapsed/refractory chronic lymphocytic leukemia (abstract 105) and three investigator-led studies (79, 166, 167), plus five posters (1932, 1933, 1957, 2109, 2716). Genmab has 22 epcoritamab abstracts at the meeting (six oral presentations, 14 posters and two publication-only abstracts).Confirmed datePrimary source
2026-12-12$INCYINCYTEAt the 68th American Society of Hematology (ASH) Annual Meeting in New Orleans, Incyte will give two oral presentations on Saturday, December 12, 2026: Phase 1 data for INCA033989 (mutCALR antibody) in JAK-inhibitor-naive myelofibrosis, 4:00-4:15 p.m. CT / 5:00-5:15 p.m. ET (publication 409), and results from the Phase 3 frontMIND study of tafasitamab in patients with partial metabolic response, 4:30-4:45 p.m. CT / 5:30-5:45 p.m. ET (publication 405); plus three posters, 5:30-7:30 p.m. CT / 6:30-8:30 p.m. ET (2755, 2766, 2478). Incyte has more than 30 abstracts at the meeting.Confirmed datePrimary source
2026-12-12$IRONDISC MEDICINE INCAt the 68th American Society of Hematology (ASH) Annual Meeting in New Orleans, on Saturday, December 12, 2026 Disc Medicine will give an oral presentation of RALLY-MF Phase 2 efficacy data for selcodebart (DISC-0974) in anemia of myelofibrosis (#242, 2:15-2:30 p.m. EST) and an oral presentation of preclinical bitopertin data in a mouse model of erythropoietic protoporphyria (#326, 4:15-4:30 p.m. EST), and will present posters with preliminary results of the Phase 1b trial of DISC-3405 in sickle cell disease (#1180) and preclinical selcodebart data in an IBD mouse model (#1123), both 5:30-7:30 p.m. EST. The clinical study abstracts published on November 4 contain previously presented data; new data and analyses are reserved for the meeting.Confirmed datePrimary source
2026-12-12$KPTIKaryopharm Therapeutics Inc.At the 68th American Society of Hematology (ASH) Annual Meeting in New Orleans, Karyopharm will give an oral presentation of the Phase 2 SENTRY-2 study of selinexor monotherapy in JAK inhibitor-naive myelofibrosis on Saturday, December 12, 2026, 2:45-3:00 p.m. CT (3:45-4:00 p.m. ET; publication 244), and present a poster with updated results from STOMP Arm 12 (selinexor, mezigdomide and dexamethasone in relapsed/refractory multiple myeloma), 5:30-7:30 p.m. CT (publication 2242).Confirmed datePrimary source
2026-12-12$LEGNLegend Biotech CorporationAt the 68th American Society of Hematology (ASH) Annual Meeting in New Orleans, Legend Biotech will give two oral presentations on Saturday, December 12, 2026 (session 655): the first analysis of the CITADEL observational study, in which IEC-parkinsonism after CARVYKTI (cilta-cel) was 1.6% with a preemptive steroid strategy versus 2.9% in historical data (#272), and CARTITUDE-4 subgroup analyses in daratumumab-refractory relapsed/refractory multiple myeloma, with nearly 60% of patients progression-free at 30 months after infusion and median overall survival not reached (#276); plus two CARVYKTI posters (#2272, #2273).Confirmed dateSEC filing
2026-12-12$MRNAModerna, Inc.At the 68th American Society of Hematology (ASH) Annual Meeting in New Orleans, Moderna will give an oral presentation of initial results from the first-in-human Phase 1/2 MyEngage trial (NCT07116616) of mRNA-2808, a multiplexed mRNA therapeutic encoding BCMA-, GPRC5D- and FcRH5-targeted T-cell engagers, in relapsed/refractory multiple myeloma on Saturday, December 12, 2026, 2:15-2:30 p.m. CT (3:15-3:30 p.m. ET), abstract #266. At abstract submission, 12 heavily pretreated patients (median 10 prior lines) had received mRNA-2808; four confirmed responses (two VGPRs, two PRs) were observed among 11 response-evaluable patients, with no dose-limiting toxicities or treatment-related serious adverse events. Moderna expects to present updated data at the meeting.Confirmed datePrimary source
2026-12-12$RIGLRigel Pharmaceuticals, Inc.At the 68th American Society of Hematology (ASH) Annual Meeting in New Orleans, Rigel will present data from the ongoing Phase 1b study of R289, a dual IRAK1/4 inhibitor, in relapsed/refractory lower-risk myelodysplastic syndrome in an oral session on Saturday, December 12, 2026, 3:00-3:15 p.m. CT (4:00-4:15 p.m. ET), publication #251 (Guillermo Garcia-Manero, MD). As of July 16, 2026, 64 patients were enrolled (33 in dose escalation, 31 in dose expansion); updated data as of a planned mid-November data cut, including preliminary efficacy data from the dose expansion phase, will be presented. The same day, 5:30-7:30 p.m. CT, two TAVALISSE (fostamatinib) posters in immune thrombocytopenia (#1250 and #1252).Confirmed datePrimary source
2026-12-12$SNDXSyndax Pharmaceuticals, Inc.At the 68th American Society of Hematology (ASH) Annual Meeting in New Orleans, Syndax presentations on Saturday, December 12, 2026 include two oral presentations: preclinical data on differential responses to menin inhibitors in KMT2A-rearranged ALL and AML (publication 47, session 9:30-11:00 a.m. CT) and the ALLG AMLM26 INTERCEPT trial of revumenib as pre-emptive therapy for measurable residual disease in NPM1-mutated or KMT2A-rearranged AML (publication 388, session 4:00-5:30 p.m. CT); plus posters on revumenib in relapsed/refractory therapy-related KMT2A-rearranged AML (1669) and an AGAVE-201 subgroup analysis of axatilimab in chronic GVHD (2478), 5:30-7:30 p.m. CT. Syndax had 19 abstracts accepted at the meeting (14 revumenib, including seven oral presentations; five axatilimab); times are session times.Confirmed datePrimary source
2026-12-12$XBIOXenetic Biosciences, Inc.At the 68th American Society of Hematology (ASH) Annual Meeting in New Orleans, Xenetic Biosciences' research on a mechanism of resistance to CAR T-cell therapy and its reversal by DNase I will be presented orally on Saturday, December 12, 2026, 4:00-4:15 p.m. CT (5:00-5:15 p.m. ET), publication number 427, in session 702 "Overcoming Resistance and Escape in CAR-T Cell Therapy": "Extracellular chromatin released during CAR T-cell killing establishes a self-reinforcing resistance niche reversed by DNase I", presented by Alexey Stepanov, Ph.D., of Scripps Research. It is a research presentation; no clinical trial results are announced.Confirmed datePrimary source
2026-12-13$AAPGASCENTAGE PHARMA GROUP INTERNATIONALAt the 68th American Society of Hematology (ASH) Annual Meeting in New Orleans, Ascentage Pharma Group International will give an oral presentation on Sunday, December 13, 2026, 10:00-10:15 a.m. CT (publication #513; Qingqing Cai, MD, Sun Yat-sen University Cancer Center) disclosing for the first time clinical data on APG-5918, an EED inhibitor, in relapsed/refractory T-cell lymphoma. As of July 30, 2026, 95 patients with advanced malignancies (67 with R/R TCL) had been enrolled. Among 47 efficacy-evaluable R/R TCL patients, the objective response rate was 44.7% (2 complete responses, 19 partial responses) and the disease control rate was 74.5%; among 20 patients treated at the 600 mg QD dose, the objective response rate was 65.0% (10.0% complete responses) with a 95.0% disease control rate. No dose-limiting toxicities were observed, and the company is proposing 600 mg QD as the recommended Phase 2 dose. The same day, the company will present two posters, 6:00-8:00 p.m. CT: olverembatinib combined with blinatumomab and de-intensified chemotherapy in pediatric patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia (publication #3303; as of July 21, 2026, 40 patients enrolled, 100% complete remission rate at days 19, 48 and 90), and olverembatinib and lisaftoclax combined with azacitidine or homoharringtonine in venetoclax-relapsed/refractory acute myeloid leukemia (publication #3388; as of July 23, 2026, 33 patients enrolled, overall response rate 30% with azacitidine and 33.3% with homoharringtonine).Confirmed dateFinviz (news)
2026-12-13$ADCTADC Therapeutics SAAt the 68th American Society of Hematology (ASH) Annual Meeting in New Orleans, updated results from the Phase 1b LOTIS-7 study of ZYNLONTA (loncastuximab tesirine) plus glofitamab in relapsed or refractory large B-cell lymphoma will be presented orally on Sunday, December 13, 2026, 12:00-12:15 p.m. CT (1:00-1:15 p.m. ET; abstract #619; Juan P. Alderuccio, MD, Sylvester Comprehensive Cancer Center). As of the June 15, 2026 data cutoff, at the 150 µg/kg starting dose, the overall response rate was 88.7% and the complete response rate 75.3% among 97 efficacy-evaluable patients; cytokine release syndrome occurred in 32% of treated patients and three Grade 5 treatment-emergent adverse events were reported.Confirmed datePrimary source
2026-12-13$AGIOAgios Pharmaceuticals, Inc.At the 68th American Society of Hematology (ASH) Annual Meeting in New Orleans, Agios will present the first AG-236 clinical data, from a Phase 1 single ascending dose study in 24 healthy volunteers, in a poster on Sunday, December 13, 2026, 6:00-8:00 p.m. CT (7:00-9:00 p.m. ET; #3772). AG-236 was well tolerated at all dose levels (1.0, 3.0 and 9.0 mg/kg), with no serious adverse events and no dose-limiting toxicities; the company says the data support every-six-month dosing in polycythemia vera.Confirmed datePrimary source
2026-12-13$CGEMCullinan Therapeutics, Inc.At the 68th American Society of Hematology (ASH) Annual Meeting in New Orleans, Cullinan Therapeutics will present updated Phase 1 dose-escalation data for CLN-049, its FLT3xCD3 T cell engager, in relapsed/refractory acute myeloid leukemia and myelodysplastic syndrome in a poster on Sunday, December 13, 2026 (poster 3385, Hall F). The abstract reports anti-leukemic activity at the selected Phase 2 target doses of 6 µg/kg and 12 µg/kg and a favorable safety profile for the double step-up dosing regimen; updated results for the selected Phase 2 regimens will be detailed in the poster. The same day Cullinan will present a Trial in Progress poster on velinotamig in immune thrombocytopenia and warm autoimmune hemolytic anemia (poster 3001).Confirmed dateSEC filing
2026-12-13$CLYMClimb Bio IncAt the 68th American Society of Hematology (ASH) Annual Meeting in New Orleans, Climb Bio will present new clinical data for budoprutug, its anti-CD19 monoclonal antibody, in previously treated primary immune thrombocytopenia in a poster on Sunday, December 13, 2026, 6:00-8:00 p.m. CT (7:00-9:00 p.m. ET), poster 3003, session 311: safety, B-cell depletion and platelet data from all three dose cohorts of the ongoing Phase 1b trial.Confirmed datePrimary source
2026-12-13$CRDFCardiff Oncology, Inc.Updated data from an investigator-sponsored clinical trial of onvansertib in chronic myelomonocytic leukemia (CMML) will be presented at the American Society of Hematology (ASH) Annual Meeting on December 13, 2026, according to Cardiff Oncology. Presentation time not announced.Confirmed datePrimary source
2026-12-13$CRSPCRISPR Therapeutics AGAt the 68th American Society of Hematology (ASH) Annual Meeting in New Orleans, CRISPR Therapeutics will present clinical data from the ongoing Phase 1/2 trial of zugocabtagene geleucel (zugo-cel), its allogeneic CD19 CAR T cell therapy, in relapsed or refractory large B-cell lymphoma in an oral presentation on Sunday, December 13, 2026 at 5:15 p.m. CT (6:15 p.m. ET), abstract 706: "Zugocabtagene geleucel (zugo-cel), an off-the-shelf CRISPR-Cas9 engineered CD19 CAR T cell therapy demonstrates dose-dependent efficacy in highly refractory large B-cell lymphoma".Confirmed datePrimary source
December 12-13, 2026$DMRADAMORA THERAPEUTICS INCDamora Therapeutics will present new preclinical data on DMR-001, its pan-mutant mutCALR-targeted antibody for essential thrombocythemia and myelofibrosis, showing an average 95-fold improvement in anti-proliferative potency against 10 non-Type 1 CALR mutations versus a reference antibody (poster, December 12, 2026), plus a trial-in-progress poster on the CLARITY-101 Phase 1/1b study (December 13, 2026), both at the 68th ASH Annual Meeting.Conference rangeFinviz (news)
2026-12-13$GERNGeron CorporationAt the 68th American Society of Hematology (ASH) Annual Meeting in New Orleans, Geron will present three posters on Sunday, December 13, 2026: the Phase 1/1b IMAGINE trial of imetelstat and azacitidine with or without venetoclax in relapsed acute myeloid leukemia (#3402), and two preclinical posters on imetelstat in acute myeloid leukemia (#3244) and on KAT6A-rearranged leukemia (#1698). No results are reported in advance.Confirmed datePrimary source
2026-12-13$GMABGenmab A/SAt the 68th American Society of Hematology (ASH) Annual Meeting in New Orleans, Genmab epcoritamab presentations on Sunday, December 13, 2026 include an oral presentation of 33-month follow-up from EPCORE NHL-5 (Pola-R-CHP with epcoritamab in first-line diffuse large B-cell lymphoma; abstract 622) and six posters (3516, 3517, 3519, 3550, 3719, 4406). Genmab has 22 epcoritamab abstracts at the meeting (six oral presentations, 14 posters and two publication-only abstracts).Confirmed datePrimary source
2026-12-13$INCYINCYTEAt the 68th American Society of Hematology (ASH) Annual Meeting in New Orleans, Incyte will give an oral presentation of preclinical data on INCB203954, a JAK2V617F-selective inhibitor, on Sunday, December 13, 2026, 5:00-5:15 p.m. CT / 6:00-6:15 p.m. ET (publication 675), and present 12 posters, 6:00-8:00 p.m. CT / 7:00-9:00 p.m. ET, including inMIND results in molecularly defined high-risk follicular lymphoma (3498). Incyte has more than 30 abstracts at the meeting.Confirmed datePrimary source
2026-12-13$IRONDisc Medicine, Inc.At the 68th American Society of Hematology (ASH) Annual Meeting in New Orleans, Disc Medicine will present two posters on Sunday, December 13, 2026: baseline characteristics from the Phase 3 APOLLO trial of bitopertin in erythropoietic protoporphyria (#4209) and preclinical data on selcodebart with momelotinib in wild-type mice (#2287). The APOLLO poster covers baseline characteristics, not outcome results.Confirmed datePrimary source
2026-12-13$KPTIKaryopharm Therapeutics Inc.At the 68th American Society of Hematology (ASH) Annual Meeting in New Orleans, Karyopharm will give an oral presentation of updated 48-week results from the Phase 3 SENTRY trial of selinexor plus ruxolitinib in JAK inhibitor-naive myelofibrosis on Sunday, December 13, 2026, 10:15-10:30 a.m. CT (11:15-11:30 a.m. ET; publication 526).Confirmed datePrimary source
2026-12-13$LEGNLegend Biotech CorporationAt the 68th American Society of Hematology (ASH) Annual Meeting in New Orleans, Legend Biotech will present two posters on Sunday, December 13, 2026 (session 704): an update of the first-in-human trial of LB2501, an in vivo CD19/CD20 dual-targeting CAR-T therapy, in relapsed/refractory B-cell NHL (#4169; the abstract reports overall and complete response rates of 100% among eight patients at dose level 2, with responses lasting up to five months at data cutoff; additional data will be presented at the meeting), and an update of the Phase 1 study of LUCAR-G39D, an allogeneic CD20/CD19 dual-targeted CAR gamma delta T-cell therapy (#2392).Confirmed dateSEC filing
2026-12-13$SNDXSyndax Pharmaceuticals, Inc.At the 68th American Society of Hematology (ASH) Annual Meeting in New Orleans, Syndax presentations on Sunday, December 13, 2026 include two oral presentations in the 4:30-6:00 p.m. CT sessions: the final analysis of the Beat AML Phase 1b study of azacitidine, venetoclax and revumenib in newly diagnosed NPM1-mutated or KMT2A-rearranged AML (publication 662) and a multicenter Phase 1 trial of revumenib as post-transplant maintenance (publication 715); plus posters 6:00-8:00 p.m. CT, including updated Phase 1/2 results of revumenib with intensive chemotherapy from SNDX-5613-0708 (3406), real-world data (3403, 3424), exposure-response modeling for Phase 3 dose selection (3408) and an AGAVE-201 axatilimab correlation analysis (4252). Syndax had 19 abstracts accepted at the meeting (14 revumenib, including seven oral presentations; five axatilimab); times are session times.Confirmed datePrimary source
2026-12-13$TCRXTScan Therapeutics, Inc.TScan Therapeutics will share updated data on patients treated in Cohort C of the Phase 1 ALLOHA study of TSC-101 at the 68th ASH Annual Meeting: publication number 4178, presentation on December 13, 2026, 6:00-8:00 p.m. ET.Confirmed datePrimary source
2026-12-13$ZYMEZymeworks Inc.Zymeworks will present new preclinical data for ZW1953, a multispecific T cell engager targeting FLT3, CLEC12A and CD33 with conditional CD28 co-stimulation in AML, in a poster at the American Society of Hematology Annual Meeting on December 13, 2026.Confirmed dateSEC filing
2026-12-14$AAPGASCENTAGE PHARMA GROUP INTERNATIONALAt the 68th American Society of Hematology (ASH) Annual Meeting in New Orleans, Ascentage Pharma Group International will present a poster on Monday, December 14, 2026, 6:00-8:00 p.m. CT (publication #5069; Elias Jabbour, MD, MD Anderson Cancer Center) on olverembatinib combined with blinatumomab in 17 patients with relapsed/refractory Philadelphia chromosome-positive B-cell precursor acute lymphoblastic leukemia or chronic myeloid leukemia in lymphoid blast phase. Among evaluable patients, major molecular response was achieved in 80.0% (12/15), MR4.0 in 60.0% (9/15), complete remission in 84.6% (11/13) and MRD negativity in 83.3% (10/12); grade 3 or higher treatment-emergent adverse events occurred in 76.5% of patients, predominantly neutropenia.Confirmed dateFinviz (news)
2026-12-14$ADCTADC Therapeutics SAAt the 68th American Society of Hematology (ASH) Annual Meeting in New Orleans, three ZYNLONTA (loncastuximab tesirine) oral presentations are scheduled for Monday, December 14, 2026: the Phase II WM-NET1 trial in relapsed/refractory and high-risk Waldenström macroglobulinemia, 11:00-11:15 a.m. CT (#783); a multicenter Phase II investigator-initiated study of fixed-duration ZYNLONTA in relapsed/refractory marginal zone lymphoma, 11:15-11:30 a.m. CT (#784; ORR 93% and CRR 74.4% among 43 efficacy-evaluable patients as of July 1, 2026, two-year PFS rate 90.8%); and full results of the Phase 3 LOTIS-5 study of ZYNLONTA plus rituximab versus R-GemOx in relapsed or refractory DLBCL, 3:00-3:15 p.m. CT (4:00-4:15 p.m. ET; #920), in which median PFS by independent review was 6.14 versus 4.73 months (HR 0.73; P=0.0083) and no statistically significant difference in overall survival was observed; Grade 5 treatment-emergent adverse events occurred in 13.2% versus 4.6% of patients within the protocol-defined 105-day reporting window (1.5% versus 3.0% with a standard 30-day post-treatment window).Confirmed datePrimary source
2026-12-14$AGIOAgios Pharmaceuticals, Inc.At the 68th American Society of Hematology (ASH) Annual Meeting in New Orleans, Agios will give an oral presentation of a post hoc analysis of eGFR in the Phase 3 RISE UP trial of mitapivat in sickle cell disease on Monday, December 14, 2026, 11:00-11:15 a.m. CT (12:00-12:15 p.m. ET; #741): among 132 patients with hyperfiltration at baseline, eGFR decreased by 14.7 mL/min/1.73 m2 at Week 52 with mitapivat (n=92) versus 4.9 with placebo (n=40). The same day, a Trial in Progress poster on the Phase 3 REIGNITE trial, 6:00-8:00 p.m. CT (#4686).Confirmed datePrimary source
2026-12-14$AUTLAutolus Therapeutics plcAt the 68th American Society of Hematology (ASH) Annual Meeting in New Orleans, Autolus will present a poster on Monday, December 14, 2026 (abstract 273, publication number 5094; Aaron Logan, UCSF) comparing ddPCR and qPCR assays to monitor obecabtagene autoleucel (obe-cel) in a FELIX subset; concordance was described as sufficient to support the use of the commercially available qPCR assay in clinical practice.Confirmed datePrimary source
2026-12-14$BLSMBlossomHill Therapeutics, Inc.At the 68th American Society of Hematology (ASH) Annual Meeting in New Orleans (December 12-15, 2026), BlossomHill Therapeutics will present a poster on Monday, December 14, 2026, 7:00-9:00 p.m. ET (Ernest N. Morial Convention Center, Hall F; session 604, Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: Poster III; publication number 5000): "BH-30236, a novel macrocyclic clk inhibitor, modulates alternative splicing in AML and HR MDS through regulating phosphorylation and expression of srsf family proteins", with preclinical and clinical data for BH-30236.Confirmed datePrimary source
December 12 and 14, 2026$CLRBCellectar Biosciences, Inc.Cellectar Biosciences will present three posters on iopofosine I 131 in Waldenstrom macroglobulinemia at the 68th ASH Annual Meeting: updated 12-month CLOVER WaM follow-up data showing longer duration of response after fewer prior therapy lines (December 12, 2026, publications #1799 and #1790), and detailed design of the planned Phase 3 confirmatory study versus rituximab-based chemotherapy in BTKi-pretreated patients (December 14, 2026, publication #5325). The company continues to target a 1H2027 FDA filing for accelerated approval, with Phase 3 first patient dosing anticipated 1Q2027.Conference rangeFinviz (news)
December 13-14, 2026$COAGHemab Therapeutics Holdings, Inc.Hemab Therapeutics will present first clinical PK/PD data for sutacimig in congenital Factor VII deficiency (Phase 2b, two participants dosed as of July 24, 2026, prothrombin time shortened >50% after a single dose) on December 14, 2026, and preclinical data for HMB-003 (a plasmin inhibitor for heavy menstrual bleeding) on December 13, 2026, both as posters at the 68th ASH Annual Meeting in New Orleans.Conference rangeFinviz (news)
December 12 and 14, 2026$CRBUCaribou Biosciences, Inc.Caribou Biosciences announced two oral presentations and one poster on its discontinued CAR-T programs vispa-cel and CB-011 at the 2026 ASH Annual Meeting (December 12-15, New Orleans): CB-011 multiple myeloma data (CaMMouflage trial) on December 12, and vispa-cel lymphoma data (ANTLER trial) on December 14, plus a related poster. The abstracts were submitted before Caribou's announcement of plans to discontinue further development of both allogeneic CAR-T programs due to the financing environment for allogeneic CAR-T.Conference rangeFinviz (news)
2026-12-14$CRVSCorvus Pharmaceuticals, Inc.Corvus Pharmaceuticals announced that initial Phase 2 data (NIAID/NIH-led trial) on soquelitinib for autoimmune lymphoproliferative syndrome (ALPS) will be presented in a poster at the 68th ASH Annual Meeting on December 14, 2026, 6:00-8:00pm (publication #4743). As of August 3, 2026, three ALPS patients completed one year of treatment at 200mg twice daily with no grade 3/4 adverse events; all discontinued background steroids.Confirmed dateFinviz (news)
Dec 12-14, 2026$GILDGILEAD SCIENCES, INC.Gilead Sciences and Kite, a Gilead Company, announced on November 4, 2026 that they will deliver 23 presentations, including 7 oral presentations, at the 68th American Society of Hematology (ASH) Annual Meeting in New Orleans (December 12-15, 2026). Confirmed oral presentations include an 18-month-or-longer follow-up update from the Phase 2 iMMagine-1 trial of anito-cel (anitocabtagene autoleucel) in relapsed/refractory multiple myeloma and the GEM-AnitoFIRST study, both on Saturday, December 12; an update from the DESCAR-T real-world registry for Yescarta (axicabtagene ciloleucel) on Saturday, December 12; the CABI pre-axi-cel study and the ENCORE-1 double-dose axi-cel study, both on Sunday, December 13; and the GELTAMO LATE-R axi-cel study plus a CAR T TmCD19-IL18 presentation, both on Monday, December 14. Poster presentations include five-year follow-up data from the ZUMA-12 trial of Yescarta in high-risk first-line large B-cell lymphoma (Saturday, December 12), matching-adjusted indirect comparisons (MAIC) of anito-cel versus teclistamab/talquetamab and versus ciltacabtagene autoleucel (Sunday, December 13), first global clinical data for gamgertamig (CM336/OM336, partnered with Lakefront Biotherapeutics) in immune cytopenias including immune thrombocytopenia (ITP) and autoimmune hemolytic anemia (AIHA) (Sunday, December 13), updates from the Phase 1 PALISADES-1 study of KITE-753 in relapsed/refractory B-cell lymphoma (Monday, December 14), and data on brexucabtagene autoleucel (Tecartus) consolidation in Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia (Monday, December 14). The BLA for anito-cel is separately under FDA review with a PDUFA target action date of December 23, 2026.Conference rangePrimary source
2026-12-14$GMABGenmab A/SAt the 68th American Society of Hematology (ASH) Annual Meeting in New Orleans, Genmab will present the primary results of the Phase 3 EPCORE DLBCL-4 trial of fixed-duration epcoritamab plus lenalidomide (E-Len) versus R-GemOx in relapsed or refractory diffuse large B-cell lymphoma in an oral presentation on Monday, December 14, 2026 (abstract 919); the results will also be highlighted in the ASH 2026 Press Program. The same day, three posters (5441, 5462, 5463, the latter on health-related quality of life in EPCORE DLBCL-4). Genmab has 22 epcoritamab abstracts at the meeting (six oral presentations, 14 posters and two publication-only abstracts).Confirmed datePrimary source
2026-12-14$HURATuHURA Biosciences, Inc.TuHURA Biosciences will present three posters on the role of its Delta Opioid Receptor (DOR) technology in controlling myeloid-derived suppressor cells (MDSCs), T regs and M2 macrophages, at the 68th American Society of Hematology (ASH) Annual Meeting in New Orleans, on Monday, December 14, 2026, 6:00-8:00pm ET (abstracts 4725, 4721, 4744).Confirmed dateFinviz (news)
2026-12-14$IMMXImmix Biopharma, Inc.Immix Biopharma's NXC-201 NEXICART-2 trial results (45-patient safety and efficacy data, the first U.S. CAR-T trial in relapsed/refractory AL amyloidosis) were selected for oral presentation at the 68th ASH Annual Meeting in New Orleans, on Monday, December 14, 2026 at 11:15am CT (publication #826).Confirmed dateFinviz (news)
2026-12-14$IMNMIMMUNOME, INC.Immunome expects to present an updated Phase 1 dataset for IM-1021 at the 2026 American Society of Hematology (ASH) Annual Meeting on December 14, 2026.Confirmed dateSEC filing
2026-12-14$INCYINCYTEAt the 68th American Society of Hematology (ASH) Annual Meeting in New Orleans, Incyte will give two oral presentations on Monday, December 14, 2026: long-term data from the Phase 1/2 open-label extension of latarcibart (VGA039) prophylaxis in von Willebrand disease, 3:30-3:45 p.m. CT / 4:30-4:45 p.m. ET (publication 880), and Phase 1 data for INCA033989 in essential thrombocythemia, 4:45-5:00 p.m. CT / 5:45-6:00 p.m. ET (publication 1034); plus seven posters, 6:00-8:00 p.m. CT / 7:00-9:00 p.m. ET, including Phase 1 data for INCA033989 alone or with ruxolitinib in relapsed/refractory myelofibrosis (5576) and the Phase 3 EXCALIBUR-ET2 trial in progress (5526). Incyte has more than 30 abstracts at the meeting.Confirmed datePrimary source
2026-12-14$IRONDisc Medicine, Inc.At the 68th American Society of Hematology (ASH) Annual Meeting in New Orleans, Disc Medicine will give an oral presentation of the ongoing open-label Phase 2 RESTORE-PV trial of DISC-3405 in polycythemia vera on Monday, December 14, 2026 (#929, 3:45-4:00 p.m. EST), and present a poster on a cellular model of congenital erythropoietic porphyria (bitopertin program; #4621, 6:00-8:00 p.m. EST) the same day.Confirmed datePrimary source
2026-12-14$RIGLRigel Pharmaceuticals, Inc.At the 68th American Society of Hematology (ASH) Annual Meeting in New Orleans, Rigel will present a poster on hemoglobin responses with fostamatinib in a long-term extension trial in warm autoimmune hemolytic anemia (71 patients; publication #4619) on Monday, December 14, 2026, 6:00-8:00 p.m. CT (7:00-9:00 p.m. ET). Fostamatinib remains investigational in this setting.Confirmed datePrimary source
2026-12-14$RLAYRELAY THERAPEUTICS INCAt the 68th American Society of Hematology (ASH) Annual Meeting, an oral presentation on Monday, December 14, 2026, 4:00-4:15 p.m. ET / 3:00-3:15 p.m. CT (abstract 878, presenter Dr. Bryan Sisk): updated results from part 1 of the ReInspire study of zovegalisib in adults and adolescents with PIK3CA-driven vascular malformations. Relay plans a corporate conference call on December 14 after the presentation to review the data, provide a regulatory update and an overview of next steps; call details are to be provided later.Confirmed dateSEC filing
2026-12-14$SLNSilence Therapeutics plcAt the 68th American Society of Hematology (ASH) Annual Meeting in New Orleans, Silence Therapeutics will present data from its SANRECO Phase 2 randomized, double-blind study of divesiran, an siRNA silencing TMPRSS6, in polycythemia vera in an oral presentation on Monday, December 14, 2026, 3:30-3:45 p.m. CT (4:30-4:45 p.m. ET), publication number 928, session 634.Confirmed datePrimary source
2026-12-14$SLSSELLAS LIFE SCIENCES GROUP INCAt the 68th American Society of Hematology (ASH) Annual Meeting in New Orleans, SELLAS Life Sciences will present results from its completed Phase 2 study of SLS009 (tambiciclib) with azacitidine and venetoclax in relapsed/refractory acute myeloid leukemia after prior venetoclax in a poster on Monday, December 14, 2026, 6:00-8:00 p.m. CT (7:00-9:00 p.m. ET), abstract 5155 (Joshua F. Zeidner, MD). At the selected dose (30 mg twice weekly) the announcement reports overall response rates of 57% in TP53-mutated AML and 54% in monocytic AML; across all doses (59 patients) the overall response rate was 34%.Confirmed datePrimary source
2026-12-14$SNDXSyndax Pharmaceuticals, Inc.At the 68th American Society of Hematology (ASH) Annual Meeting in New Orleans, Syndax presentations on Monday, December 14, 2026 include three oral presentations: preclinical data on KMT2A and LEDGF mutations driving cross-resistance to menin inhibitors (publication 760, session 10:30 a.m.-12:00 p.m. CT), and, in the 2:45-4:15 p.m. CT sessions, the update of the Phase 2 SAVE study of the all-oral combination of revumenib, decitabine/cedazuridine and venetoclax in newly diagnosed AML (publication 904) and revumenib monotherapy enabling patients with relapsed/refractory acute leukemia to proceed to stem cell transplant (publication 905); plus posters 6:00-8:00 p.m. CT (5170, 5557, 5995, 6012), including long-term AGAVE-201 efficacy and safety of axatilimab in chronic GVHD (5995). Syndax had 19 abstracts accepted at the meeting (14 revumenib, including seven oral presentations; five axatilimab); times are session times.Confirmed datePrimary source
December 12-15, 2026 (ASH 2026)$COGTCOGENT BIOSCIENCES INCOn November 5, 2026, Cogent Biosciences said it plans to present multiple posters featuring bezuclastinib at the 68th ASH Annual Meeting, December 12-15, 2026 in New Orleans, including more detailed SUMMIT analyses of effects on skin and neurocognitive symptoms, longer-term pathobiology follow-up, an MS2D2 comparison of symptom burden in nonadvanced systemic mastocytosis before and after treatment with that of the general population, and the first look at clinical results from the SUMMIT sub-study of patients switching from avapritinib to bezuclastinib.Conference rangeSEC filing
December 12-15, 2026$KURAKura Oncology, Inc.Kura Oncology and Kyowa Kirin announced that eight abstracts on ziftomenib (four oral presentations, four posters) were accepted at the 2026 ASH Annual Meeting (December 12-15, New Orleans), including first clinical results combining ziftomenib with the FLT3 inhibitors quizartinib (KOMET-007) and gilteritinib (KOMET-008) in NPM1/FLT3 co-mutated AML, longer-term KOMET-007 data with venetoclax/azacitidine, and a KOMET-001 analysis of ziftomenib monotherapy beyond NPM1/KMT2A-defined AML. The companies will host an investor webcast on December 15, 2026 at 8:30am ET.Conference rangeFinviz (news)
ASH 2026, December 12-15$KYTXKyverna Therapeutics, Inc.Kyverna Therapeutics will present additional one-year biomarker data from KYSA-8, its registrational trial of miv-cel in stiff person syndrome, at the American Society of Hematology (ASH) 2026 Annual Meeting (December 12-15, 2026). The presentation day and time have not been announced.Conference rangeSEC filing
ASH 2026, December 12-15$MBRXMoleculin Biotech, Inc.At the 68th American Society of Hematology (ASH) Annual Meeting in New Orleans, December 12-15, 2026, Moleculin will present a poster, "A Pivotal Phase 2/3 Study of Naxtarubicin as Second Line Therapy in Patients with AML", with results from the first prespecified interim analysis of the MB-108 (MIRACLE) Phase 2/3 trial of Annamycin plus cytarabine in relapsed or refractory acute myeloid leukemia (Hall F, Ernest N. Morial Convention Center). Among the first 45 randomized patients, complete remission rates were 43% and 36% in the two Annamycin arms versus 12% with placebo; these interim data had already been disclosed. The session date and time have not yet been disclosed. The second interim analysis is expected in early 2027.Conference rangePrimary source
ASH, December 12-15, 2026$PRLDPrelude Therapeutics IncorporatedPrelude will present two posters at the 68th American Society of Hematology (ASH) Annual Meeting (New Orleans, LA, December 12-15, 2026): a Trials in Progress abstract on the enrolling Phase 1 study of PRT12396, its mutant-selective JAK2V617F inhibitor, and preclinical data on the lead development candidate of its mCALR-targeted degrader antibody conjugate (DAC) program. The presentation days have not been specified.Conference rangePrimary source
December 14-16, 2026$BCAXBicara Therapeutics Inc.Bicara Therapeutics will present preclinical data on the effect of tumor-targeted TGF-beta neutralization with ficerafusp alfa on fibrosis and drug penetration at the ESMO Immuno-Oncology & Advanced Therapies Congress 2026, December 14-16 in London. The presentation day has not been specified.Conference rangeSEC filing
December 14-16, 2026$NCNANuCana plcNuCana plans three presentations on NUC-7738, including the NuTide:701 expansion study results and translational data, at the ESMO Immuno-Oncology & Advanced Therapies Congress 2026, December 14-16, 2026, in London.Conference rangeSEC filing
December 13-16, 2026$VYGRVoyager Therapeutics, Inc.Voyager Therapeutics will present a poster at the Antibody Engineering & Therapeutics US 2026 Conference, December 13-16, 2026, on its Voyager NeuroShuttle platform, including the identification and characterization of ALPL antibodies and in vivo pharmacokinetics in mice and non-human primates. Announced November 5, 2026.Conference rangeSEC filing
2026-12-17$NRXPNRx Pharmaceuticals, Inc.NRx Pharmaceuticals will hold its 2026 Annual Meeting of Stockholders on December 17, 2026 at 10:00 a.m. Eastern Time in virtual-only format, according to the definitive proxy statement dated November 5, 2026.Confirmed dateSEC filing
2026-12-25$NGENNervGenNervGen's at-the-market (ATM) program will be terminated on December 25, 2026, in advance of the company's expected transition to U.S. domestic issuer reporting status. Through November 16, 2026, no common shares had been sold under the program.Confirmed datePrimary source

Investor conferences and corporate events in December 2026

Investor and corporate events: 94 events

Date / windowTickerCompanyEventStatusSources
2026-12-01$ALXOALX Oncology Holdings Inc.ALX Oncology leadership will participate in a fireside chat and one-on-one meetings at the Piper Sandler Annual Healthcare Conference in New York on Tuesday, December 1, 2026 (fireside chat at 3:30 PM EST).Confirmed datePrimary source
2026-12-01$BCRXBioCryst Pharmaceuticals, Inc.BioCryst will present at the 9th Annual Evercore Healthcare Conference in Coral Gables, FL on Tuesday, December 1, 2026 at 8:45 a.m. ET, with a live audio webcast and replay in the Investors & Media section of the company website. An investor conference appearance, not a data release.Confirmed datePrimary source
2026-12-01$CERSCerus CorporationCerus Corporation management will hold one-on-one meetings at Citi's 2026 Global Healthcare Conference in Miami, Florida, on Tuesday, December 1, 2026. An investor conference appearance, not a data release.Confirmed dateFinviz (news)
2026-12-01$CLDXCelldex Therapeutics, Inc.Celldex management will participate in a fireside chat at the 9th Annual Evercore Healthcare Conference on Tuesday, December 1, 2026 at 10:50 a.m. ET; webcast on the Events and Presentations page of the Investors section of the Celldex website, with replay for 90 days. An investor conference appearance, not a data release.Confirmed datePrimary source
2026-12-01$COAGHemab Therapeutics Holdings, Inc.Hemab Therapeutics management will participate in a fireside chat at the 9th Annual Evercore Healthcare Conference in Coral Gables, Florida on Tuesday, December 1, 2026 at 3:00 p.m. ET, with a webcast and replay on the company's website.Confirmed datePrimary source
2026-12-01$COGTCogent Biosciences, Inc.Cogent Biosciences will participate in the Piper Sandler Healthcare Conference on December 1, 2026 at 11:00 a.m. ET, with a live webcast on the Investors & Media page of its website and a replay archived for up to 30 days. Announced November 5, 2026.Confirmed dateSEC filing
2026-12-01$CRBPCorbus Pharmaceuticals Holdings, Inc.Corbus Pharmaceuticals CEO Yuval Cohen, Ph.D., will participate in a fireside chat and one-on-one investor meetings at the 9th Annual Evercore Healthcare Conference on Tuesday, December 1, 2026 at 10:25 a.m. EST, with a webcast.Confirmed datePrimary source
2026-12-01$DFTXDefinium Therapeutics, Inc.Definium Therapeutics management will participate in a fireside chat at the 9th Annual Evercore Healthcare Conference in Coral Gables, FL on Tuesday, December 1, 2026 at 3:50 p.m. ET. An investor conference appearance, not a data release.Confirmed datePrimary source
2026-12-01$DNLIDenali Therapeutics Inc.Denali Therapeutics will present at the 9th Annual Evercore Healthcare Conference on Tuesday, December 1, 2026, from 10:50 to 11:10 a.m. ET, with a live webcast.Confirmed datePrimary source
2026-12-01$FDMT4D Molecular Therapeutics, Inc.4DMT management will participate in a fireside chat at the 9th Annual Evercore Healthcare Conference on Tuesday, December 1, 2026 at 8:45 a.m. ET; archived webcasts will be available on the company investor website. An investor conference appearance, not a data release.Confirmed datePrimary source
2026-12-01$GILDGILEAD SCIENCES, INC.Gilead will present at Citi's Global Healthcare Conference on Tuesday, December 1, 2026 at 11:00 a.m. ET, with a live webcast on the investor-relations website.Confirmed datePrimary source
2026-12-01$GLUEMonte Rosa Therapeutics, Inc.Monte Rosa Therapeutics management will participate in a fireside chat at the Piper Sandler 38th Annual Healthcare Conference (New York, NY) on Tuesday, December 1, 2026 at 3:30 p.m. ET, with a webcast in the Events & Presentations section of the company's website, archived for 30 days.Confirmed datePrimary source
2026-12-01$INOInovio Pharmaceuticals, Inc.INOVIO will take part in a fireside chat at the Piper Sandler 38th Annual Healthcare Conference in New York on Tuesday, December 1, 2026 at 2:00-2:25 p.m. EST, with a live webcast and a replay available for 90 days; members of the management team will also hold one-on-one meetings with investors.Confirmed datePrimary source
2026-12-01$INSPInspire Medical Systems, Inc.Inspire Medical Systems management will present at the Piper Sandler 38th Annual Healthcare Conference on Tuesday, December 1, 2026 at 3:00 p.m. ET, with a live webcast and a replay for two weeks on the company's investor website. An investor conference appearance, not a data release.Confirmed datePrimary source
2026-12-01$IONSIONIS PHARMACEUTICALS INCIonis management will take part in a fireside chat at Citi's 2026 Global Healthcare Conference on Tuesday, December 1, 2026; time not announced. A live webcast will be available in the Investors & Media section of the Ionis website, with a replay within 48 hours, archived for a limited time.Confirmed datePrimary source
2026-12-01$JSPRJasper Therapeutics, Inc.Jasper Therapeutics will reconvene its adjourned special meeting of stockholders on Tuesday, December 1, 2026 at 10:00 a.m. Pacific Time, virtually via live audio webcast; the record date remains September 28, 2026 and the proposals are unchanged.Confirmed dateSEC filing
2026-12-01$KODKodiak Sciences Inc.Kodiak Sciences Chief Executive Officer Victor Perlroth, M.D., will present at the 9th Annual Evercore Healthcare Conference in Miami on Tuesday, December 1, 2026 at 7:55-8:15 a.m. ET, with a live webcast in the Events and Presentations section of the company's investor relations website and a replay available for a limited time.Confirmed datePrimary source
2026-12-01$KRYSKRYSTAL BIOTECH INCKrystal Biotech management will take part in a fireside chat at the 9th Annual Evercore Healthcare Conference in Coral Gables, Florida, on December 1, 2026, at 2:10 pm ET.Confirmed datePrimary source
2026-12-01$MDGLMadrigal Pharmaceuticals, Inc.Madrigal Pharmaceuticals will participate in a fireside chat at the 9th Annual Evercore Healthcare Conference on Tuesday, December 1, 2026 at 8:20 a.m. ET, with a live webcast on the Investor Relations Events page of the company website. An investor conference appearance, not a data release.Confirmed datePrimary source
2026-12-01$MLYSMineralys Therapeutics, Inc.Mineralys Therapeutics senior management will participate in a fireside chat at the 9th Annual Evercore Healthcare Conference on Tuesday, December 1, 2026 at 1:45 p.m. ET. Live webcasts and archives are on the News & Events page of the Investor Relations section of the company website. An investor conference appearance, not a data release.Confirmed datePrimary source
2026-12-01$NEONeoGenomics, Inc.NeoGenomics will participate in a fireside chat at the Piper Sandler 38th Annual Healthcare Conference in New York on Tuesday, December 1, 2026, at 4:00 p.m. EST, with a live and archived webcast on its investor relations website.Confirmed datePrimary source
2026-12-01$OLMAOlema Pharmaceuticals, Inc.Olema Oncology will take part in a fireside chat at the Citi's 2026 Global Healthcare Conference (Miami, FL) on December 1, 2026 at 1:00 p.m. ET. A live webcast and recording will be available, as permitted by the event host, on Olema's investor relations website.Confirmed datePrimary source
2026-12-01$PCVXVAXCYTE INCVaxcyte will take part in a fireside chat at the Evercore Healthcare Conference (November 30 to December 2) live on Tuesday, December 1, 2026 at 9:35 a.m. ET / 6:35 a.m. PT. Webcast replays on investors.vaxcyte.com for approximately 30 days. An investor conference appearance, not a data release.Confirmed dateSEC filing
2026-12-01$PTCTPTC Therapeutics, Inc.PTC Therapeutics executives will speak at the Citi 2026 Global Healthcare Conference on Tuesday, December 1, 2026 at 9:40 a.m. ET, with a live webcast on the Events and Presentations page of the Investors section of the company's website, archived for 30 days.Confirmed datePrimary source
2026-12-01$RXRXRecursion Pharmaceuticals, Inc.Recursion will participate in Citi's 2026 Global Healthcare Conference on Tuesday, December 1, 2026, with webcasts in the events section of its investor relations website.Confirmed datePrimary source
2026-12-01$SRRKScholar Rock Holding CorporationScholar Rock management will participate in a fireside chat at the 9th Annual Evercore Healthcare Conference in Miami on Tuesday, December 1, 2026 at 8:45 a.m. ET, with a live webcast on the Events and Presentations page of the company investor website and a replay available for approximately 90 days. An investor conference appearance, not a data release.Confirmed datePrimary source
2026-12-01$SYRESpyre Therapeutics, Inc.Members of the Spyre Therapeutics management team will take part in a fireside chat and one-on-one investor meetings at the 9th Annual Evercore Healthcare Conference in Miami on Tuesday, December 1, 2026 at 3:00 p.m. ET, with a live audio webcast and replay on the company's investor events page.Confirmed datePrimary source
2026-12-01$TARSTARSUS PHARMACEUTICALS INCTarsus Pharmaceuticals management plans to participate in a fireside chat at the Piper Sandler 38th Annual Healthcare Conference on Tuesday, December 1, 2026 at 11:30 a.m. PT / 2:30 p.m. ET, with a live webcast in the events section of the company's website (announced November 5, 2026).Confirmed datePrimary source
2026-12-01$TLSITriSalus Life Sciences, Inc.TriSalus Life Sciences CEO Mary Szela and CFO David Patience will hold one-on-one meetings and present at the Piper Sandler 38th Annual Healthcare Conference on Tuesday, December 1, 2026 at 8:10 a.m. ET; a webcast replay will be available for 90 days. An investor conference appearance, not a data release.Confirmed datePrimary source
2026-12-01$TLXTelix Pharmaceuticals LimitedTelix Pharmaceuticals General Meeting of shareholders on Tuesday, December 1, 2026, at 10:00 a.m. (Melbourne time; Monday, November 30, 2026, 6:00 p.m. ET), at The Events Centre, Level 5, Tower 2/727 Collins Street, Melbourne, and online. The meeting relates to the proposed acquisition of ITM Isotope Technologies Munich SE announced on September 21, 2026 (total upfront consideration valued at US$1.65 billion, plus contingent consideration of up to US$700 million tied to future regulatory approvals and commercial sales milestones for ITM-11). Items of business: approval of the issue of Maximum Upfront Consideration Shares, of Regulatory Milestone Consideration Shares and of Future Sales Milestone Consideration Shares (each under ASX Listing Rule 7.1); election of two new Directors with effect from Closing; and approval of grants of share rights to those two new Non-Executive Directors under the Equity Incentive Plan (ASX Listing Rule 10.14).Confirmed dateSEC filing
2026-12-01$TRAXFIRST TRACKS BIOTHERAPEUTICS INCFirst Tracks Biotherapeutics executives will hold a fireside chat and one-on-one investor meetings at the Piper Sandler 38th Annual Healthcare Conference in New York on Tuesday, December 1, 2026 at 1:30 p.m. ET. Live webcast on the investor section of the company website (ir.firsttracksbio.com/news-events/events), with replays for at least 30 days. An investor conference appearance, not a data release.Confirmed datePrimary source
2026-12-01$TRDAEntrada Therapeutics, Inc.Entrada Therapeutics lists the Evercore Healthcare Conference in Miami, FL on December 1, 2026 among its upcoming investor conferences in its third-quarter 2026 release (November 5, 2026); time and format not given.Confirmed dateSEC filing
2026-12-01$VRTXVERTEX PHARMACEUTICALS INCORPORATEDVertex investor relations executives will participate in a fireside chat at the 9th Evercore Healthcare Conference on Tuesday, December 1, 2026 at 4:15 p.m. EST, with a live webcast in the Investors section of www.vrtx.com and an archived replay. An investor conference appearance, not a data release.Confirmed datePrimary source
2026-12-01$VTRSViatris Inc.Viatris will participate in a fireside chat at the 9th Annual Evercore Healthcare Conference on December 1, 2026 at 8:45 a.m. ET, with a live session and archived replay at investor.viatris.com.Confirmed datePrimary source
2026-12-01$XENEXenon Pharmaceuticals Inc.Xenon Pharmaceuticals will present in a fireside chat at the 9th Annual Evercore Healthcare Conference in Coral Gables, FL on Tuesday, December 1, 2026, 7:55-8:15 a.m. EST. Webcast details are on the Investors section of the company website; dates and times are subject to change. An investor conference appearance, not a data release.Confirmed datePrimary source
2026-12-01$XERSXERIS BIOPHARMA HOLDINGS INCXeris Biopharma senior management will participate in one-on-one meetings and a fireside chat at the Piper Sandler Healthcare Conference in New York on Tuesday, December 1, 2026; the fireside chat will be webcast live in the Events section of the investor relations website. Time not given.Confirmed dateSEC filing
2026-12-02$ADPTAdaptive Biotechnologies CorporationAdaptive Biotechnologies will participate in a fireside chat at the Piper Sandler 38th Annual Healthcare Conference in New York on Wednesday, December 2, 2026, at 4:00 p.m. ET.Confirmed datePrimary source
2026-12-02$ANABANAPTYSBIO, INCAnaptysBio CFO Chris Murphy will take part in a fireside chat and one-on-one investor meetings at the Piper Sandler 38th Annual Healthcare Conference in New York on Wednesday, December 2, 2026 at 8:00 a.m. ET, with a live webcast on the investor section of the company's website and replays available for at least 30 days.Confirmed datePrimary source
2026-12-02$ANABANAPTYSBIO, INCAnaptysBio president and CEO Daniel Faga will take part in a fireside chat at the 9th Annual Evercore Healthcare Conference in Miami on Wednesday, December 2, 2026 at 10:50 a.m. ET, with a live webcast on the investor section of the company's website and replays available for at least 30 days.Confirmed datePrimary source
2026-12-02$AQSTAquestive Therapeutics, Inc.Aquestive Therapeutics President and CEO Daniel Barber will present at the Piper Sandler 38th Annual Healthcare Conference (December 1-3, 2026, New York City) on Wednesday, December 2, 2026, at 10:30 a.m. ET; the company will also host one-on-one investor meetings that day. A webcast will be available on the Events and Presentations page of the Investors section of the company's website, with a replay for 30 days. Announced November 18, 2026. An investor conference appearance, not a data release.Confirmed datePrimary source
2026-12-02$ARWRArrowhead PharmaceuticalsArrowhead Pharmaceuticals will hold fireside chats on December 2, 2026 at Citi's 2026 Global Healthcare Conference (2:20 p.m. EST) and at the Piper Sandler 38th Annual Healthcare Conference (3:00 p.m. EST).Confirmed datePrimary source
2026-12-02$BEAMBeam Therapeutics Inc.Beam Therapeutics management will participate in a fireside chat at the 9th Annual Evercore Healthcare Conference in Miami on Wednesday, December 2, 2026 at 8:20 a.m. ET.Confirmed datePrimary source
2026-12-02$BMEABiomea Fusion, Inc.Biomea Fusion management will participate in one-on-one investor meetings at Citi's 2026 Global Healthcare Conference in Miami on December 2, 2026. Investor meetings only; no presentation or data release announced.Confirmed datePrimary source
2026-12-02$CERSCerus CorporationCerus Corporation management will hold one-on-one meetings at the Piper Sandler 38th Annual Healthcare Conference in New York on Wednesday, December 2, 2026. An investor conference appearance, not a data release.Confirmed dateFinviz (news)
2026-12-02$CSTLCastle Biosciences, Inc.Castle Biosciences executive management will present a company overview at the Piper Sandler 38th Annual Healthcare Conference on Wednesday, December 2, 2026 at 8:10 a.m. ET, with a live audio webcast and replay on the company's investor relations website.Confirmed datePrimary source
2026-12-02$DFTXDefinium Therapeutics, Inc.Definium Therapeutics management will participate in a fireside chat at the Piper Sandler 38th Annual Healthcare Conference in New York on Wednesday, December 2, 2026 at 4:00 p.m. ET. An investor conference appearance, not a data release.Confirmed datePrimary source
2026-12-02$FDMT4D Molecular Therapeutics, Inc.4DMT management will participate in a fireside chat at the Citi Global Healthcare Conference 2026 on Wednesday, December 2, 2026 at 3:00 p.m. ET; archived webcasts will be available on the company investor website. An investor conference appearance, not a data release.Confirmed datePrimary source
2026-12-02$GILDGILEAD SCIENCES, INC.Gilead will present at the Annual Evercore Healthcare Conference on Wednesday, December 2, 2026 at 11:40 a.m. ET, with a live webcast on the investor-relations website.Confirmed datePrimary source
2026-12-02$IONSIONIS PHARMACEUTICALS INCIonis management will take part in a fireside chat at the Piper Sandler 38th Annual Healthcare Conference on Wednesday, December 2, 2026; time not announced. A live webcast will be available in the Investors & Media section of the Ionis website, with a replay within 48 hours, archived for a limited time.Confirmed datePrimary source
2026-12-02$KRYSKRYSTAL BIOTECH INCKrystal Biotech management will take part in a fireside chat at Citi's 2026 Global Healthcare Conference in Miami on December 2, 2026, at 10:20 am ET.Confirmed datePrimary source
2026-12-02$MDGLMadrigal Pharmaceuticals, Inc.Madrigal Pharmaceuticals will participate in a fireside chat at the Piper Sandler 38th Annual Healthcare Conference on Wednesday, December 2, 2026 at 8:30 a.m. ET, with a live webcast on the Investor Relations Events page of the company website. An investor conference appearance, not a data release.Confirmed datePrimary source
2026-12-02$NRIXNurix Therapeutics, Inc.Nurix management will participate in a fireside chat at the Piper Sandler Annual Healthcare Conference on Wednesday, December 2, 2026, at 3:30 p.m. ET.Confirmed datePrimary source
2026-12-02$OLMAOlema Pharmaceuticals, Inc.Olema Oncology will take part in a fireside chat at the Piper Sandler 38th Annual Healthcare Conference (New York, NY) on December 2, 2026 at 1:30 p.m. ET. A live webcast and recording will be available, as permitted by the event host, on Olema's investor relations website.Confirmed datePrimary source
2026-12-02$PACBPacific Biosciences of California, Inc.PacBio management will participate in a fireside chat at the Piper Sandler 38th Annual Healthcare Conference in New York, NY on Wednesday, December 2, 2026 at 9:30 a.m. ET, with a live webcast at investor.pacificbiosciences.com and a replay for at least 30 days. Announced November 17, 2026. An investor conference appearance, not a data release.Confirmed datePrimary source
2026-12-02$PHVSPharvaris N.V.Pharvaris will take part in a fireside chat at the 9th Annual Evercore Healthcare Conference (Miami, November 30-December 2, 2026) on Wednesday, December 2, 2026 at 10:00 a.m. EST, with a live audio webcast in the Investors section of the Pharvaris website and a replay available for 30 days.Confirmed dateSEC filing
2026-12-02$PRLDPrelude Therapeutics IncorporatedPrelude Therapeutics CEO Kris Vaddi, CSO Peggy Scherle and CFO Bryant Lim will participate in a fireside chat at the 9th Annual Evercore Healthcare Conference in Coral Gables, FL, on Wednesday, December 2, 2026 at 7:55 a.m. ET.Confirmed datePrimary source
2026-12-02$RZLTRezolute, Inc.Virtual annual meeting on December 2, 2026 at 3:00 p.m. Pacific. Stockholders will consider increasing authorized common shares from 165 million to 225 million. The proposal remains subject to a vote; authorized shares are not shares already issued.Confirmed dateSEC filing
2026-12-02$SRRKScholar Rock Holding CorporationScholar Rock management will participate in a fireside chat at the Citi 2026 Global Healthcare Conference in Miami on Wednesday, December 2, 2026 at 3:40 p.m. ET, with a live webcast on the Events and Presentations page of the company investor website and a replay available for approximately 90 days. An investor conference appearance, not a data release.Confirmed datePrimary source
2026-12-02$STROSutro Biopharma, Inc.Sutro Biopharma fireside chat at the Piper Sandler 38th Annual Healthcare Conference on December 2, 2026 at 1:30 p.m. EST. An investor conference appearance, not a data release.Confirmed datePrimary source
2026-12-02$SYRESpyre Therapeutics, Inc.Members of the Spyre Therapeutics management team will take part in a fireside chat and one-on-one investor meetings at Citi's 2026 Global Healthcare Conference in Miami on Wednesday, December 2, 2026 at 9:40 a.m. ET, with a live audio webcast and replay on the company's investor events page.Confirmed datePrimary source
2026-12-02$TRAXFIRST TRACKS BIOTHERAPEUTICS INCFirst Tracks Biotherapeutics executives will hold a fireside chat and one-on-one investor meetings at the 9th Annual Evercore Healthcare Conference in Miami on Wednesday, December 2, 2026 at 12:30 p.m. ET. Live webcast on the investor section of the company website (ir.firsttracksbio.com/news-events/events), with replays for at least 30 days. An investor conference appearance, not a data release.Confirmed datePrimary source
2026-12-02$VKTXViking Therapeutics, Inc.Viking Therapeutics management will participate in a fireside chat and investor meetings at the Piper Sandler 38th Annual Healthcare Conference in New York, NY; the fireside chat is on Wednesday, December 2, 2026, 2:00-2:25 p.m. ET, with a live webcast in the Investors & Media section of the company website and a replay afterwards. An investor conference appearance, not a data release.Confirmed datePrimary source
2026-12-02$VTVTvTv Therapeutics Inc.vTv Therapeutics will take part in the 9th Annual Evercore HealthCONx Conference in Coral Gables, Florida, on December 2, 2026, with a fireside presentation and one-on-one investor meetings. Announced November 5, 2026.Confirmed dateSEC filing
2026-12-02$ZVRAZevra Therapeutics, Inc.Members of Zevra Therapeutics' executive leadership team will present at the Piper Sandler 38th Annual Healthcare Conference in New York, NY on Wednesday, December 2, 2026, at 1:00 p.m. ET; management will also be available for one-on-one meetings with registered attendees. A live webcast link will be on the Events & Presentations page of the Investor Relations section at investors.zevra.com. Announced November 18, 2026. An investor conference appearance, not a data release.Confirmed datePrimary source
2026-12-03$ATYRaTyr Pharma, Inc.aTyr Pharma President and CEO Sanjay S. Shukla, M.D., M.S., will participate in a fireside chat at the Piper Sandler 38th Annual Healthcare Conference in New York on Thursday, December 3, 2026 at 2:00 p.m. ET, with one-on-one meetings and a webcast on the company's website.Confirmed datePrimary source
2026-12-03$BMEABiomea Fusion, Inc.Biomea Fusion will take part in a fireside chat at the Piper Sandler 38th Annual Healthcare Conference in New York on December 3, 2026 at 1:30 p.m. ET, and management will hold one-on-one investor meetings during the conference; a live audio webcast will be available on the News & Events page of the company website, with a replay afterwards. An investor conference appearance, not a data release.Confirmed datePrimary source
2026-12-03$ENSCEnsysce Biosciences, Inc.Cy Biopharma management (Ensysce Biosciences) will give a company presentation at the 38th Annual Piper Sandler Healthcare Conference in New York on Thursday, December 3, 2026, 2:10-2:30 p.m. ET.Confirmed datePrimary source
2026-12-03$FDMT4D Molecular Therapeutics, Inc.4DMT management will participate in a fireside chat at the Piper Sandler 38th Annual Healthcare Conference on Thursday, December 3, 2026 at 8:30 a.m. ET; archived webcasts will be available on the company investor website. An investor conference appearance, not a data release.Confirmed datePrimary source
2026-12-03$FULCFulcrum Therapeutics, Inc.Fulcrum Therapeutics will hold a virtual special meeting of stockholders on Thursday, December 3, 2026 at 9:00 a.m. ET (www.proxydocs.com/FULC; record date October 28, 2026) to vote on the share issuance and change of control in the merger with Slate Medicines, a reverse stock split in a range of 1-for-10 to 1-for-80, the 2026 Stock Plan, the 2026 ESPP and adjournment. The first two proposals are conditions to closing. Definitive proxy statement/prospectus filed November 4, 2026.Confirmed dateSEC filing
Dec 1-3, 2026$KRROKorro Bio, Inc.Korro Bio lists Citi's 2026 Global Healthcare Conference, December 1-3, 2026 among its upcoming conferences in its third-quarter 2026 release (November 5, 2026); the release does not give the day, time or format of its participation.Conference rangeSEC filing
Dec 1-3, 2026$KRROKorro Bio, Inc.Korro Bio lists the Piper Sandler 38th Annual Healthcare Conference, December 1-3, 2026 among its upcoming conferences in its third-quarter 2026 release (November 5, 2026); the release does not give the day, time or format of its participation.Conference rangeSEC filing
2026-12-03$TRAWTraws Pharma, Inc.Traws Pharma will hold its 2026 Special Meeting of Stockholders in virtual format on Thursday, December 3, 2026 at 9:00 a.m. ET, to vote on granting the Board of Directors discretionary authority to effect a reverse stock split of all issued and outstanding common stock at a ratio of not less than 1-for-8 and not greater than 1-for-15, to be determined by the Board within twelve months of stockholder approval, and on a possible adjournment; record date October 6, 2026.Confirmed dateSEC filing
December 1-3, 2026$UPBUpstream Bio, Inc.Upstream Bio expects to participate in the 38th Annual Piper Sandler Healthcare Conference in New York (December 1-3, 2026); presentation day not specified.Conference rangeSEC filing
2026-12-04$IRDOpus Genetics, Inc.December 4, 2026 is the last day to exercise the March 2025 warrants called by Opus Genetics: after call notices delivered on October 22, 2026 to the holders of all 2,859,105 March 2025 warrants outstanding at September 30, 2026, holders may exercise them for cash at $0.95 per share until 6:30 p.m. New York City time on December 4, 2026; warrants not exercised by then will be cancelled in exchange for $0.001 per warrant share. Through the issuance of the third-quarter 2026 financial statements, 2,078,947 of these warrants had been exercised, for proceeds of $2.0 million, according to the Form 10-Q.Confirmed dateSEC filing
2026-12-08$LGNDLIGAND PHARMACEUTICALS INCLigand will hold its annual Investor Day on Tuesday, December 8, 2026, from 10:30 a.m. to 12:00 p.m. ET in New York, with presentations on strategy, investment activity, the royalty portfolio and the long-term financial outlook; Palvella's CEO will discuss QTORIN rapamycin as a guest speaker. A live webcast will be available.Confirmed datePrimary source
2026-12-08$OCSOculis Holding AGOculis R&D Day on December 8, 2026, with updates on the late-stage pipeline, including privosegtor and licaminlimab.Confirmed datePrimary source
2026-12-09$NXTCNextCure, Inc.NextCure will hold a special meeting of stockholders on December 9, 2026, at 9:00 a.m. ET (record date November 3, 2026) to vote on the proposed merger with Avere Therapeutics; subject to approval and closing conditions, the combined company is expected to operate as Avere and trade on Nasdaq under the ticker AVRX.Confirmed dateSEC filing
2026-12-10$FDMT4D Molecular Therapeutics, Inc.4DMT management will participate in a fireside chat at the Barclays Virtual Ophthalmology Day on Thursday, December 10, 2026 at 10:30 a.m. ET; archived webcasts will be available on the company investor website. An investor conference appearance, not a data release.Confirmed datePrimary source
2026-12-10$OGNOrganon & Co.Payment date of December 10, 2026 for Organon’s declared quarterly dividend of $0.02 per common share, for holders of record at the close of business November 9.Confirmed datePrimary source
2026-12-11$TAKTakeda Pharmaceutical Company LimitedTakeda will host a Capital Markets Day on December 11, 2026, in Tokyo, Japan, as announced with its FY2026 first-half results on October 29, 2026. Event time not announced in the release.Confirmed datePrimary source
2026-12-11$TPSTTempest Therapeutics, Inc.Tempest Therapeutics will reconvene its special meeting of stockholders on December 11, 2026 at 12:00 p.m. ET via live webcast, after adjourning it again on November 12, 2026 for lack of sufficient votes. The proposal, which requires 75% of the votes entitled to be cast, would replace specified supermajority voting requirements and permit stockholder action by written consent.Confirmed dateSEC filing
2026-12-12$INCYINCYTEIncyte will host an in-person and virtual analyst and investor event during the ASH Annual Meeting on Saturday, December 12, 2026, 7:30-9:00 p.m. CT (8:30-10:00 p.m. ET), with a webcast; a replay will be available for 30 days in the Investor section of Incyte.com.Confirmed datePrimary source
2026-12-14$AGIOAgios Pharmaceuticals, Inc.Agios will host an ASH 2026 virtual investor event on Monday, December 14, 2026 at 1:00 p.m. ET (12:00 p.m. CT), with a live webcast in the Investors section of its website; a replay will be available approximately two hours after the event.Confirmed datePrimary source
2026-12-14$ENSCEnsysce Biosciences, Inc.Ensysce Biosciences disclosed that, effective immediately following the company's annual shareholders meeting scheduled for December 14, 2026, President James Morrisson will become Chief Executive Officer, and current CEO Dr. Lynn Kirkpatrick (CEO since January 2009) will become Chief Operating Officer. Board member Will Chang has also notified the company of his intention to resign from the board after the annual meeting. No financial terms were disclosed for Kirkpatrick's new role beyond a contract amendment confirming the title change will not trigger severance payments.Confirmed dateSEC filing
2026-12-14$MBOTMicrobot Medical Inc.2026 annual meeting of stockholders on Monday, December 14, 2026, set by the Board of Directors on October 14, 2026. Record date: October 15, 2026. The exact time and location will be specified in the proxy statement for the meeting.Confirmed dateSEC filing
2026-12-14$SNDXSyndax Pharmaceuticals, Inc.Syndax will host an in-person investor event with a live webcast during the ASH Annual Meeting on Monday, December 14, 2026, 7:00-8:30 a.m. CT / 8:00-9:30 a.m. ET; members of the management team will be joined by key opinion leaders to discuss key data presented at the meeting. A replay will be available for a limited time on the Investor section of the company's website.Confirmed datePrimary source
Supporting source
2026-12-15$BLLNBillionToOne, Inc.BillionToOne plans to make Northstar Clear, a tissue-free MRD test for patients with all solid tumors, commercially available on December 15, 2026 (announced November 4, 2026). Company launch plan.Confirmed dateSEC filing
2026-12-15$OSCROscar Health, Inc.HealthCare.gov deadline: enroll by December 15, 2026 for Marketplace coverage starting January 1, 2027 (Open Enrollment started November 1 and ends January 15, 2027). Relevant to Oscar Health's individual Marketplace (ACA) business.Confirmed datePrimary source
SEC filing
2026-12-16$GMABGenmab A/SGenmab will hold its virtual 2026 R&D Update and ASH Data Review on Wednesday, December 16, 2026 at 10:30 a.m. ET (4:30 p.m. CET), with a live webcast; registration and the webcast link are on genmab.com. The event is not an official ASH program.Confirmed datePrimary source
2026-12-16$IRONDisc Medicine, Inc.Disc Medicine management will host a conference call following the ASH meeting on Wednesday, December 16, 2026 at 8:00 a.m. ET to review highlights of the presented data and plans for next steps in development; registration is on the company's Events and Presentations page.Confirmed datePrimary source
2026-12-16$KPTIKaryopharm Therapeutics Inc.Under the Bidding Procedures Order of November 3, 2026 in Karyopharm's Chapter 11 case, the deadline for bids for the company's assets is December 16, 2026 at 4:00 p.m. Central Time; the determination of qualified bids is set for December 18, 2026, and an auction is scheduled for December 21, 2026 if applicable. Ayrmid is the approved stalking horse bidder.Confirmed dateSecondary source
2026-12-21$KPTIKaryopharm Therapeutics Inc.Under the Bidding Procedures Order of November 3, 2026 in Karyopharm's Chapter 11 case, an auction for the company's assets is scheduled for December 21, 2026 at 10:00 a.m. Central Time, if applicable. If no qualified bid other than the stalking horse bid from Ayrmid is received by the December 16 bid deadline, no auction will be held: the stalking horse bid from Ayrmid becomes the successful bid and the debtors may proceed to seek confirmation of the Chapter 11 plan.Confirmed dateSecondary source
2026-12-22$OCGNOcugen, Inc.Postponed special meeting of stockholders on the proposal to increase authorized common stock by 250,000,000 shares: Tuesday, December 22, 2026, 8:00 a.m. ET, virtual. Record date: close of business October 30, 2026. The meeting had previously been adjourned to October 26, 2026; the board postponed it on October 14, 2026.Confirmed dateSEC filing
2026-12-31$IPHAInnate Pharma S.A.On November 5, 2026, Innate Pharma announced that Chief Financial Officer Frédéric Lombard will step down from his position on December 31, 2026, to pursue new career opportunities; the company has initiated a search for a successor.Confirmed dateSEC filing

Educational and informational content only. It is not financial advice or a recommendation to buy or sell any security. Verify each event on the linked primary source before relying on it, and consult a licensed advisor for investment decisions.